of Galcanezumab in Patients With COVID-19
disease 2019 (COVID-19) is an infectious respiratory disease caused
by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
previously referred to as "2019 novel coronavirus."1
Lilly and Company has not studied the use of galcanezumab in patients
should use their clinical judgment in determining the most
appropriate approach in treating a patient with galcanezumab who has
confirmed or suspected COVID-19.
mAbs Have no Direct Specific Immunomodulatory Effect
CGRP mAbs have been engineered to bind to either the CGRP peptide or
receptor with high specificity and minimized interaction with the
also referred to as immunoglobulins, are composed of 2 identical
heavy and 2 identical light chains.3
These chains contain variable and constant sections, involved in
antigen binding and biological activity, respectively. Five isotypes
exist in humans including IgA, IgD, IgE, IgG, and IgM. Therapeutic
mAbs are composed of IgG isotypes which are divided into 4
subclasses in order of decreasing serum concentrations including IgG1
mAbs are introduced into the host for a specific purpose.3
is a humanized IgG4 mAb that
the most current information regarding the coronavirus, please refer
to the WHO website;
Coronavirus disease (COVID-19) outbreak
World Health Organization. Naming the coronavirus disease (COVID-19)
and the virus that causes it.
Accessed March 11, 2020.
Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus
on calcitonin gene-related peptide for prophylactic migraine therapy.
Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what
headache specialists need to know. Headache.
Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for
the use of monoclonal antibodies in migraine. Headache.
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
= calcitonin gene-related peptide
= immunoglobulin A
= immunoglobulin D
= immunoglobulin E
= immunoglobulin G
= immunoglobulin G (subclass) 4
= immunoglobulin M
= monoclonal antibody
= World Health Organization
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.